Drugmakers Tibotec and Gilead Sciences have joined forces to create a complete antiretroviral regimen contained in a single pill taken once daily. In July, the companies announced they were collaborating on a combination medication including Tibotec's experimental NNRTI TMC278 (rilpivirine) and Gilead's Truvada, which itself is a two-drug combo of Emtriva and Viread.
Tibotec is studying the combination of the medications dosed separately in its ongoing Phase III clinical trial of TMC278. Currently, the only single-tablet regimen for the treatment of HIV is Atripla, jointly marketed by Gilead and Bristol-Myers Squibb.
